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KAJIAN MENGENAI POLIMORFISME GEN MTHFR PADA PESAKIT 
REKAHAN OROFASIAL TANPA SINDROM SERTA IBU BAPA MEREKA 
 
Abstrak 
Tesis ini menggambarkan perkaitan antara polimorfisme nukleotida tunggal (SNP) 
gen MTHFR 677CT dan 1298AC dengan rekahan orofacial dalam populasi 
Malayu. Dua kaedah kajian, kes kawalan dan ujian ketakseimbangan penularan 
(TDT) telah digunakan. Subjek terdiri dari 53 pesakit Malayu yang mengalami 
orofacial rekah, 53 ibu, 49 bapa dan 49 kawalan untuk kajian kes kawalan. 38 triad 
kesuluruhan ibu-bapa dan kanak-kanak telah dikaji untuk alel-alel varian daripada 
ibubapa kepada anak-anak dengan menggunakan TDT. Klasifikasi genotip dilakukan 
menggunakan PCR dan diikuti oleh RFLP serta gel elektroforesis. Frekuensi MTHFR 
SNP 677CT pada kumpulan kawalan telah didapati lebih rendah (14.3%) jika 
dibandingkan dengan populasi  am Kaukasia 30% pada sesetengah kajian. Walau 
bagaimanapun, prevalens 1298AC pada kumpulan kawalan (28.5%) adalah sama 
dengan populasi lain (27-36%). Prevalens MTHFR 677 CT heterozygus genotip pada 
populasi ibu (n=53), didapati semasa penentuan genotip ibu pada lokus 677 
dijalankan, adalah lebih rendah (5.6%) jika dibandingkan dengan kumpulan yang 
dikawal tanpa orofasial rekah (14.3%). Tetapi perbezaan ini adalah secara 
statistiknya tidak signifikan (P=0.340). Frefuensi alel T pada ibu (4.7%) juga adalah 
lebih rendah daripada yang dikawal (9.2%). TDT juga tidak menunjukkan penularan 
yang rendah secara signifiken aleh T dari ibu kepada anak (P=0.38), tetapi risiko 
penularan aleh T dari ibu yang membawa alel ini adalah rendah dibandingkan 
dengan alel liar jenis C (OR=0.59, 95% CI=0.187-1.921 ). Hal ini menunjukkan 
terdapat kemungkinan alel T ibu memainkan peranan dalam melindungi daripada 
 xiv 
rekahan orofacial. Tiada perkaitan dijumpai antara genotip MTHFR 677CT anak atau 
bapa dengan rekahan orofasial. Tiada perkaitan dilihat antara genotip MTHFR 
1298AC dari sebarang kumpulan (ibu, bapa atau anak) dengan risiko rakahan 
orofasial. Analisis empat haplotip (677C/1298A, 677C/1298C, 677T/1298A, 
677T/1298C) yang diambil dari  genotip gabungan/ sebatian menunjukkan 
pengedaran asimetri haplotip yang menandakan perkaitan ketakseimbungaan antara 
kedua-dua loci (MTHFR 677CT and 1298AC), konsisten dengan dapatan kajian-
kajian lain. Ujian penularan, TDT menunjukkan penularan haplotip yang rendah 
secara signifikan 677T/1298A dari ibubapa kepada anak (P=0.018), dan hal ini 
menunjukkan perkaitan songsang haplotip ini dengan rekahan orofasial. Purata 
serum folat adalah tinggi pada kajian kumpulan ibu dan juga kumpulan ibu yang 
dikawal. Sejarah pengambilan multivitamin yang mengandungi folat semasa 
mengandung didapati pada 83% ibu. Dapatan ini menolak kemungkinan status folat 
rendah pada ibu mengandung sebagai faktor risiko untuk rekahan orofasial. Kajian 
yang lebih besar untuk populasi Malayu perlu dijalankan untuk mengesahkan 
dapatkan kajian ini.  
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A STUDY OF MTHFR GENE POLYMORPHISMS IN PATIENTS 
WITH NONSYNDROMIC OROFACIAL CLEFTS AND THEIR 
PARENTS 
 
Abstract 
 
This thesis describes the association of two important MTHFR gene single nucleotide 
polymorphisms 677CT and 1298AC with orofacial clefts in the Malay 
population. Two study methods, Case control and Transmission disequilibrium test 
(TDT) were employed. The subjects included 53 Malay patients with orofacial clefts, 
53 mothers, 49 fathers and 49 controls for the case control study. Thirty eight 
complete triads of mother-father-child were studied for transmission of variant 
alleles from parents to offspring by using TDT.  The genotyping was done by 
Polymerase Chain Reaction (PCR) followed by restriction fragment length 
polymorphism (RFLP) and gel electrophoresis. The frequency of MTHFR SNP 
677CT in the control group was found to be lower (14.3%) than that in Caucasian 
general populations (30% in some studies). However, the prevalence of 1298AC in 
the control group (28.5%) was similar to that of other populations (27-36%).  The 
prevalence of MTHFR 677 heterozygous CT genotype in the maternal population 
(n=53), was found to be lower (5.6%) compared to that in controls without orofacial 
clefts (14.3%) but the difference was not statistically significant (P=0.340). The TDT 
did not show a significantly low transmission of T allele from mothers to offspring 
either (P=0.38), but the risk of transmitting the T allele from mothers carrying this 
allele was lower compared to that of the wild type C allele (OR=0.59, 95% 
CI=0.187-1.921). This indicated a possible protective role of maternal T allele in 
orofacial clefts in the present study. No association was found between MTHFR 
 xvi 
677CT genotypes of child or father with orofacial clefts. No association was seen 
between MTHFR 1298AC genotypes of any group (mother, father or child) with the 
risk of orofacial clefts. Analysis of the four haplotypes (677C/1298A, 677C/1298C, 
677T/1298A, 677T/1298C) derived from compound genotypes, showed an 
asymmetric distribution of haplotypes indicating linkage disequilibrium between 
these 2 loci (MTHFR 677CT and 1298AC), consistent with previous study findings. 
The test of transmission, TDT showed a significantly low transmission of haplotype 
677T/1298A from parents to offspring (P=0.018) indicating an inverse association of 
this haplotype with orofacial clefts. The average serum folate was high in the study 
group mothers as well as in control mothers. A history of multivitamin containing 
folate intake during pregnancy was found in 83% of mothers. These findings ruled 
out the possibility of low maternal folate status as a risk factor for orofacial clefts. 
Larger studies in the Malay population are needed to confirm the present findings. 
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CHAPTER ONE 
INTRODUCTION 
 
Orofacial clefts are a common malformation involving the face. Non 
syndromic orofacial clefts are best understood as a multifactorial disorder meaning 
that genes and environmental factors are both responsible for it. A study of the 
genetic factors in orofacial clefts showed that many genes have a role in causation of 
nonsyndromic orofacial clefts and no single gene can be pinpointed. Methylene 
tetrahydrofolate reductase (MTHFR) is one of the genes and folic acid deficiency is 
one of the environmental factors thought to be important in the causation of this 
defect. While folic acid is clearly beneficial in reducing the risk of neural tube 
defects, its role in prevention of orofacial clefts is less definite. Though controversy 
exists, a recent meta- analysis of 17 studies supported the protective role of folic acid 
supplementation in pregnancy in cleft lip with or without cleft palate and more so in 
cleft palate alone . Genetic polymorphisms in the enzymes of folic acid and one 
carbon metabolic pathway could be associated with risk of orofacial clefts, possibly 
interacting with low maternal folic acid intake. The MTHFR gene, the other genes 
and environmental factors in orofacial clefts are discussed further in the review of 
literature (Chapter 2, Sections 2.3). 
1.1 Orofacial clefts 
Orofacial clefts are one of the most common birth defects in humans. The 
prevalence of orofacial clefts worldwide is 2 per thousand on an average (Murray, 
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2002a). Transcription factors, signalling molecules and proteins are involved in 
formation of palate and lip. Orofacial clefts can result from breakdown of any of the 
mechanisms which control the cascade of events involving these factors or 
molecules. Based on embryological origin and inheritance patterns, cleft lip with or 
without cleft palate (CL/P) and cleft palate (CP) are the main types of orofacial clefts 
(Christensen and Fogh-Andersen, 1993).  The development of the lip and palate are 
closely linked thereby making cleft lip with cleft palate (CLP) more common than 
any of the defects in isolation (Owens et al., 1985). Males are more commonly 
affected than females with cleft lip with cleft palate (CLP) whereas the female 
incidence is possibly higher for cleft palate alone (CP) (WHO collaborative study, 
2002). There are various types of orofacial clefts and some cases fit into syndromes 
(defined as a group of several different malformations as primary events arising from 
the same underlying cause) while others are isolated defects (nonsyndromic).  
Cleft lip is an obvious physical defect while cleft palate has to be looked for 
by examining the newborn. Orofacial clefts can be a cosmetic defect alone or may be 
extensive enough to cause speech and feeding difficulties in childhood. Treatment 
often consumes a lot of time and resources for staged surgeries, speech therapy, 
dental reconstruction and psychological support of the families are often needed. 
Surgery for cleft lip may be done as early as 6 weeks, while cleft palate (CP) is 
repaired 6 months later when the tissues have grown enough (Sandberg et al., 2002). 
Earlier repair of CP has chances of severe orodental deformities while a greater delay 
may lead to poorer speech. Hence, the timing for repair of cleft palate remains a 
controversy (Patel et al., 2006). Feeding difficulties can interfere with the nutritional 
status of an infant and must be dealt with early. Speech defects require speech 
therapy and psychological problems due to cosmetic defect need competent 
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management. Thus, the management of the patients of orofacial clefts is a process 
that starts in infancy and continues into adulthood and often there are no simple 
solutions for approaching the problems associated with orofacial clefts (Thornton et 
al., 1996).  
1.1.1 Folic acid deficiency in orofacial clefts 
Role of folate deficiency as a risk factor for orofacial clefts is important 
because it is a modifiable environmental factor. Recurrent cleft lip and palate has 
been seen in siblings of a patient with malabsorption syndrome, probably because of 
folate and B12 deficiency resulting from malabsorbtion (Faron et al., 2001). An 
increased risk of orofacial clefts with maternal use of antiepileptic drugs like 
phenytoin and phenobarbitone is also thought to be due to disturbed folic acid 
metabolism (Dansky et al., 1987). Though there is no conclusive evidence linking 
orofacial clefts and the use of any vitamin, folic acid supplementation in pregnancy 
has been shown to reduce its risk (Shaw et al., 2006, Wilcox et al., 2007).  
Based on the observation that intake of folic acid reduces the risk of orofacial 
clefts in some populations, it was suggested that variant genes involved in the folic 
acid metabolism could also be associated with the risk of oral clefts and as folic acid 
is needed for DNA and RNA synthesis, and embryonic tissues especially the 
developing palate has a high requirement of DNA production, any event which 
reduce the supply of DNA or enhanced DNA damage can theoretically result in 
orofacial clefts (Jugessur et al., 2003). 
1.1.2 Methylenetetrahydrofolate reductase (MTHFR) gene in orofacial clefts 
MTHFR gene coding for the MTHFR enzyme of folate metabolic pathway 
has been studied in orofacial clefts and maternal MTHFR polymorphisms are 
possibly more important risk factors for developing this defect rather than the child’s 
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own genotype. Moreover, the involvement of MTHFR gene is indirect because its 
polymorphic variants influencing the maternal folate status are a risk factor for 
orofacial clefts rather than the gene itself being directly responsible. Historically, the 
possibility of involvement of this gene in orofacial clefts has been investigated 
because of its association with other congenital malformations. Of all the variants of 
MTHFR gene, two of the MTHFR polymorphic variants 677CT and 1298AC, are the 
commonest and very important in the population. Other MTHFR SNPs reported are 
at bp 1059, bp 1289, bp 1317, and bp 1793 but are of unknown significance 
(Trembath et al., 1999; Rady et al., 2002).  
 MTHFR 677CT and 1298AC polymorphisms are known risk factors for 
congenital malformations like neural tube defect (Shields et al., 1999, Christensen et 
al., 1999) and possibly Down syndrome (Hobbs et al., 2000, James et al., 1999). 
Several authors have noted an association of maternal MTHFR 677CT and possibly 
maternal MTHFR 1298AC polymorphisms rather than the child’s genotype in the 
risk for developing orofacial clefts (Shaw et al., 1998, Jugessur et al., 2003, 
Martinelli et al., 2001, Pezzetti et al., 2004). Possibly, maternal MTHFR 
polymorphisms and folate deficiency act together to increase risk of orofacial clefts 
(Brouns et al., 2008). However, the association of MTHFR polymorphisms 677CT 
and 1298AC with orofacial clefts remains controversial, as several reports have 
found no association (Boyles et al., 2008, Blanton et al., 2000, Vieira et al., 2005). 
MTHFR gene polymorphisms in orofacial clefts have been reviewed further to 
answer the question regarding its association or lack of association of these SNPs 
with this malformation in the section on literature review (Chapter 2, Section 2.5.3).   
 
 5
1.1.3 Mechanism for MTHFR polymorphisms and folate deficiency causing 
orofacial clefts 
MTHFR 677CT and 1298AC polymorphisms reduce the MTHFR enzyme 
activity in the folate metabolic pathway known as the ‘methyl cycle’. It has been 
postulated that reduced enzyme activity reduces DNA methylation or supply of 
purines or cause hyperhomocysteinemia which may be harmful to the developing lip 
and palate. On the other hand, some authors have found that some of these MTHFR 
variants are inversely associated with the risk of orofacial clefts the explanations for 
which has been discussed in the Chapter 2 (Literature Review, Section 2.5.3). 
Overall, the majority of studies imply the involvement of the methyl cycle of folate 
in the risk for orofacial clefts. MTHFR 677CT and 1298AC polymorphisms imply a 
CT and AC single nucleotide change at position 677 and 1298 respectively of 
cDNA of the gene.  
1.2 SNPs and Study of SNPs 
Alterations in the genome sequence which occur commonly and do not result 
in major phenotypic alterations are known as polymorphisms. A Single Nucleotide 
Polymorphism, or SNP (pronounced "snip"), is a small genetic change, or variation 
occurring due to variation in the genetic code  specified by the four nucleotide 
"letters" A (Adenine), C (Cytosine), T (Thymine), and G (Guanine). SNP variation 
occurs when a single nucleotide, such as an A, replaces one of the other three 
nucleotide letters C, G, or T. SNP commonly occur in more than 1% of the 
population. Because SNPs occur frequently throughout the genome and tend to be 
relatively stable genetically, they serve as ‘biological markers’. As genetic markers, 
SNPs can be used to follow the inheritance patterns of chromosomal regions from 
generation to generation and are powerful tools in the study of genetic factors 
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associated with human diseases (Risch, 2000). SNPs are useful in population studies 
and genome wide scans for complex diseases and eventually physicians will be able 
to screen individuals for susceptibility to a disease just by analyzing their DNA 
samples for specific SNP patterns. SNP detection technologies have evolved from 
labor intensive, time consuming, and expensive processes to some of the most highly 
automated, efficient, and relatively inexpensive methods. However, genotyping with 
Polymerase Chain Reaction (PCR) followed by Restriction Fragment Length 
Polymorphism (RFLP) are useful for screening small number of samples and studies 
involving few SNPs. 
Polymorphisms can result in variations in the protein expression. However, 
because only about 3 to 5 percent of a person's DNA sequence codes for the 
production of proteins, most SNPs are found outside of "coding sequences". SNPs 
found within a coding sequence are of particular interest to researchers because they 
are more likely to alter the biological function of a protein. 
An "asociation study", can detect differences between the SNP patterns of the 
two groups, thereby indicating which pattern is most likely associated with the 
disease-causing gene. Another application of SNP technology is in 
pharmacogenetics, a branch of genetics studying the variable responses to the same 
drug in different individuals (Kalow, 1997). 
1.2.1 Methods of SNP detection 
The general strategy of polymorphism detection is by Polymerase Chain 
Reaction (PCR) which amplifies a small segment of the genome millions of times 
and its detection by various methods like Restriction Fragment Length 
Polymorphism (RFLP) followed by gel electrophoresis, denaturing High 
Performance Liquid Chromatography (dHPLC), sequencing and Single Stranded 
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Confirmation Polymorphism (SSCP). Analysis by SSCP is one of the most widely 
used methods for mutation detection and is based on the principle that the 
electrophoretic mobility of a molecule within the gel matrix is sensitive to the size 
and shape of the molecule. In SSCP, DNA is first amplified by PCR, and then single 
stranded DNA is generated by denaturing of the PCR product and separated on a 
nondenaturing polyacramide gel. A difference in single nucleotide between two 
sequences is sufficient to alter the folded structure of one relative to the other. This 
conformational change will migrate differently from the wild-type DNA.  
Another method that can be applied to detect unknown mutation is 
Denaturing Gradient Gel Electrophoresis (DGGE). DGGE is based on DNA 
heteroduplexes differing by a single base pair having different melting 
characteristics. The PCR products are resolved in a polyacramide gel with an 
increasing denaturing gradient of formamide and urea under careful temperature 
control. Heteroduplex DNA fragments with a single mismatched base pair are 
revealed by the differences of migration compared to the homoduplexes. However, 
the disadvantage of DGGE is the difficulty in optimization of the method.  
There are several methods available for identification of known mutations. 
These methods are much simpler than those of detecting unknown mutation 
detections but the choice is not easy (Cotton, 2000). For example, commonly used 
methods include gel-electrophoresis techniques such as PCR coupled with RFLP. 
RFLP is based on variation in the distance separating the two restriction sites; there 
will be a difference in the size of fragment and resultant differences of the position of 
the detected band. The PCR products are then digested with appropriate restriction 
enzymes and visualized by staining the gel after electrophoresis. The difference in 
size of the DNA fragments helps to detect the SNPs. However, major limitation of 
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this method is the requirement that the polymorphisms alter a restriction enzyme 
cutting site (Shi et al., 1999).  
Other detection method which is based on the selective extension of primers 
or hybridization with specific oligonucleotide probe are allele-specific PCR (ASP) or 
amplification refractory mutation system (ARMS) and oligonucleotide ligation assay 
(OLA). Usually, ARMS assay comprises of two PCRs which are conducted using the 
same substrate DNA, and it relies on one primer of a pair of PCR primers being 
specific for one allele. The specific primer for the other allelic variant is used in a 
second PCR reaction. The specificity of primer is determined by the 3’ nucleotide of 
the primer, which complements to one allele but not to the other. Oligonucleotide 
ligation assay (OLA) relies on hybridization with specific oligonucleotide probes that 
effectively discriminate between the wild type and variant sequences. The gene 
fragment containing the polymorphic site is amplified by PCR and incubated with 
probes. Ligation of the fluorescent-labeled probe to allele-specific probe occurs with 
the PCR product in the presence of thermally stable DNA ligase. The ligation 
products are separated by electrophoresis which allows the recognition of the wild-
type genotypes, variants, heterozygotes and unligated probes. If there is highly GC-
rich DNA region, it makes the allele-specific ligation step in OLA difficult to 
optimize and multiplex (Baron et al., 1996). Recently, non-gel based high-
throughput genotyping technologies are rapidly evolving to become the dominant 
genotyping platforms especially in large scale pharmacogenetic studies. Considering 
the number of gene mutations that have now been reported as more than 1000 
different human genes that cause a disease there arise a need for cost effective and 
high throughput method to identify mutation or polymorphisms in bolstering the 
progress of the analysis and diagnosis of diseases through characterization of the 
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underlying genes. One of the recent and versatile technologies for the analysis of 
genetic unknown variations is dHPLC. 
1.2.2 Use of RFLP in detection of SNPs in MTHFR gene 
Despite available modern technology, PCR followed by RFLP remains the 
standard technique used for detection of MTHFR gene SNPs. The other methods of 
detection like Amplification Refractory Mutation System (ARMS) used by some 
authors has not replaced the standard RFLP technique. Amplification Refractory 
Mutation System (ARMS) PCR has been used for detecting MTHFR C677T 
mutation (Hessner et al., 1999) as well as for MTHFR 1298 AC genotyping 
(McCarthy et al., 2004). No difference in genotyping between RFLP and sequencing 
for MTHFR 1298AC was found  (de Alvarenga et al., 2008). The only drawback of 
RFLP according to these authors is that, genotyping by analysis of electrophoresis 
gel is dependent on the observer and on the laboratory conditions (de Alvarenga et 
al., 2008). Most authors studying MTHFR 677CT have used RFLP by replication of 
methods described earlier (Frosst et al., 1995). This method is laborious; however, it 
is accurate and suitable for doing genotyping of limited sample size.  
1.3 Detection of folate deficiency 
Folate deficiency in the body can be reliably detected by doing both serum 
folate and red cell folate levels but these tests are not done routinely. Serum folate 
and B12 levels are done for patients with megaloblastic anemia or doubtful iron 
deficiency anemia. Low serum levels of folate or low RBC folate indicates that either 
dietary folate is low or absorption is poor, but does not indicate a poor tissue folate 
status. Thus serum folate estimation should be interpreted with caution as the low 
levels do not have diagnostic value. A low red cell folate has more diagnostic value 
but requires two steps in detection and is more expensive than serum folate alone 
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(www.labcorp.com/datasets/labcorp/html/chapter/mono/ri004400.htm). In order to 
institute treatment with folic acid for deficiency states, both serum folate and RBC 
folate need to be low and for thoroughness, the serum vitamin B12 level should also 
be determined. This is because more than half of the patients of low folate have B12 
deficiency. Serum folate can possibly be a screening tool for low folate and some 
people who have low folate can be further investigated with RBC folate levels 
(Bauer, 1982). 
1.4 Method of studying association: Linkage analysis and transmission 
disequilibrium test (TDT)  
Sometimes transmission disequilibrium test (TDT) is used in a genetic study 
to test for association of locus and alleles with disease. The transmission 
disequilibrium test (TDT) was proposed as a family-based association test for the 
presence of genetic linkage between a genetic marker and a trait, and it is an 
application of a statistical test called Mc Nemar’s test (Spielman et al., 1993).  
Usually the sample consists of a set of trios - affected case with their parents. 
In essence, it tests whether there are an unusually large or small number of 
transmissions of an allele, under the null hypothesis. Iles (2002) has explained TDT 
by an example which states that the probability of observing a particular allele at one 
locus is independent of the alleles observed at another locus. However, this is not the 
case when two alleles are ‘associated.’ If the frequency of allele 1 at locus 1 is p1 and 
the frequency of allele 2 at locus 2 is p2 and the two alleles are not associated, then 
the frequency with which they appear together is p1p2. If their joint frequency is 
greater than p1p2 then the two alleles are said to be positively associated. If their joint 
frequency is less than p1p2, the two alleles are said to be negatively associated. 
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Association is the non-independence of allele frequencies at different loci (Iles, 
2002).   
If a parent is heterozygous for a marker, the chances of them transmitting 
either marker allele to an affected case will be equal unless the marker is linked with 
the disease gene and unless the marker and disease are associated. A sample of cases 
and their parents is genotyped and deviations from the expected 50-50 transmission 
are observed i.e. we look for symmetrical transmission. If an allele is transmitted to 
unrelated cases more often than would be expected by chance, this implies that it is 
linked and associated with the disease mutation. If the sample contains cases related 
to each other, coming from the same pedigree, then the TDT can become a test only 
of linkage rather than association (Iles, 2002).  
1.5 Gap statement/ Justification for the study 
This study can be justified because of the following reasons: (1) Clarify 
association: Maternal MTHFR 677CT and 1298AC gene polymorphisms have been 
found to be risk factor for orofacial clefts by some authors while others have found 
no or reverse association. The review of literature highlights the various reports on 
MTHFR and orofacial clefts. From the review of literature one can see that there is a 
need for study of these SNPs in orofacial clefts for clarifying a firm association. As 
orofacial clefts are an important disorder in Malaysia, studies are needed to 
determine the association of folate and the related genes with the risk of this disease 
in the Malays. (2) Rarity of combined genetic and environment studies on orofacial 
clefts: Gene environment interaction studies are a recent phenomenon. Some 
populations and ethnic groups have a higher prevalence of orofacial clefts compared 
to others. The prevalence of orofacial clefts in Malaysians has been found to be 1.9 
per 1000 which is relatively high (Boo and Arshad, 1990). Malaysia has a 
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heterogeneous population from numerous ethnic groups and different prevalence 
have been reported from various parts of Malaysia with some areas having a higher 
than average prevalence (Ghee, 2001). (3) Clarify role of maternal folate status: 
Periconceptional folic acid supplementation has been shown to reduce the risk of 
orofacial clefts in countries like the USA where it has been found that serum folate 
level of non pregnant women is low (O'Keefe et al., 1995). Depending on the 
existing folate status of Malay women, recommendations about supplementation in 
pregnancy can be made. The folate status is dependent however, not only on dietary 
intake and folate supplementation in pregnancy, but also on the women’s genotype of 
folate metabolic genes like MTHFR (Yates et al., 1987). Thus there is a need to 
know the MTHFR 677CT and 1298AC variant status of the Malay population as well 
as the the folate status of the Malay women. In the present study, both genotype and 
nutritional status (maternal serum folate) has been studied, focussing mainly on the 
genetic aspects, to examine the role of folate metabolism in the risk for orofacial 
clefts. (4) Detect prevalence of these SNPs of MTHFR in the Malay population: 
MTHFR 677CT polymorphism had been studied widely in the Caucasians. The 
prevalence of MTHFR 677TT genotype has been found to be common in northern 
China (20%), southern Italy (26%), and Mexico (32%) (Wilcken et al., 2003). No 
studies on MTHFR prevalence are available from the Malay population. Thus, 
knowing the prevalence of MTHFR 677CT and 1298AC in the Malays would be 
useful database for future reference. 
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1.6 Objectives 
1.6.1 Main objective 
To study the Single Nucleotide Polymorphisms (SNPs) of the MTHFR 677CT and 
1298AC in the Malay patients with orofacial clefts. 
1.6.2 Specific objectives  
1) To determine the association of the MTHFR polymorphisms 677CT and 
1298AC in patients and their parents with the risk of orofacial clefts.  
2) To determine the role of individual alleles and different haplotypes derived from 
these two SNPs in the risk for orofacial clefts and to do linkage analysis.  
3) To determine the prevalence of these two SNPs in the Malay healthy control 
population. 
 4) To ascertain the folate status of mothers of patients of orofacial clefts by doing 
maternal serum folate assay and from history of folic acid containing multivitamin 
intake during pregnancy. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Prevalence of orofacial clefts  
Orofacial clefts (OMIM 119530) are the commonest facial malformation 
worldwide (Cooper, 1979). On an average, about 1 in every 500-750 live births 
results in a cleft lip and/ or palate (Peterson-Falzone, 2001). An estimated 700 
children with orofacial clefts are born every day (Tolarova et al., 2002). The 
prevalence of this developmental defect differs in different populations. Orofacial 
clefts have a birth prevalence ranging from 1/1000 to 2.69/1000 amongst different 
parts of the world (McLeod et al., 2004). This malformation is more common in 
certain Asian races compared to their western counterparts (Marazita et al., 1986b). 
2.1.1 Caucasian vs. Asian prevalence 
Ross and Johnson (1972) noted a difference among racial groups from a 
review of selected surveys. In this study, African-Americans had the lowest 
incidence with a range of 0.21 to 0.41 per 1,000 live births; Japanese, who were the 
most extensively studied among Orientals, had the highest incidence of clefts with a 
range from 1.14 to 2.13 per 1,000 live births, and in the United States and Western 
Europe whites had an incidence between 0.77 and 1.40 per 1,000 live births (Ross 
and Johnston, 1972). Certain tribes and races have a higher incidence of orofacial 
clefts (Tretsven, 1963). In Caucasian populations, the incidence of clefts lip/palate 
ranges from 1.0 to 2.21 per 1000 live births as per hospital registries (Gorlin, 1971).  
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In a study in the Chinese, done among 4,489,692 births, the prevalence of 
facial cleft at birth was reported to be 14.0/10,000 (Dai et al., 2003). The rate of 
occurrence ranges in various Chinese populations from 1.09 to 4.04 per 1000 births 
(Wong et al., 1997). In a study done in Pakistani population the incidence for cleft 
lip and/or cleft palate was found to be 1.91 per 1000 births (one per 523 births). In 
this study, Cleft lip alone was noted more frequently than isolated cleft palate and 
combined cleft lip and palate deformities (Elahi et al., 2004). From these data the 
exact prevalence cannot be ascertained as complete ascertainment of orofacial clefts 
is impossible from birth registries as many of the defects are subtle and not 
recognizable at birth; moreover, the reports include both syndromic and non 
syndromic clefts (Kozelj, 1996). The difficulty in a uniform assessment of burden of 
the disease was because many data also included cases of still birth where a higher 
prevalence of malformations is expected (Wyszynski and Wu, 2002).  
The prevalence of orofacial clefts among Caucasian and Asian populations 
has been compared in Table 2.1 below. The Caucasian incidence of orofacial clefts 
was described by Magdalenic–mestrovic (2005), while the Asian prevalence data has 
been adapted from a study by Wong (1997) and others. 
 
2.1.2 Prevalence of orofacial clefts in Malaysia 
It is well known that certain populations consistently show higher incidence 
of orofacial clefts as compared to others and therefore the racial differences are 
important in studies on orofacial clefts (Vanderas, 1987, Croen et al., 1998). 
Norway, for example, has one of the highest rates of orofacial clefts in the world 
(Abyholm, 1978).  
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Table 2.1  Data comparing the prevalence of orofacial clefts among the Caucasians 
versus Asians. Table adapted from: (Magdalenic-Mestrovic and Bagatin, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Countries Incidence per 1000 live birth Reference 
Caucasian populations 
Finland  1.74 (Rintala, 1986) 
Sweden 1.72 (Milerad et al., 1997) 
Denmark 1.89 (Jensen et al., 1988) 
Denmark 1.0-1.4 (Christensen et al., 1999) 
The Netherlands 1.47 (Owens et al., 1985) 
Germany 1.48 (Derijke et al., 1996) 
Poland 2.0-2.11 (Hillig, 1991) 
North Italy  1.33 (Shaw et al., 1995) 
 
Asian populations 
Taiwan  1.92 (Emanuel et al., 1973) 
Singapore  1.7 (Tan, 1988) 
Malaysia 1.2 (Boo and Arshad, 1990) 
China  1.4 (Dai et al., 2003) 
Korea 1.8 (Kim et al., 2002) 
Pakistan 1.91 (Elahi et al., 2004) 
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The exact prevalence of orofacial clefts among the Malay population is difficult to 
state as Malaysian data consists of heterogeneous populations and ethnic races. The 
Malaysian incidence of orofacial clefts was found to be 1.24 per 1000 live births 
(nearly 1 in 600) in a large hospital based study in Kuala Lumpur in 1987 (Boo and 
Arshad, 1990). In this data, Chinese babies had the highest incidence (1.9 per 1000) 
while Malays had the lowest (0.98 per1000) and the most common type of orofacial 
cleft was a complete unilateral cleft palate. This study was based on mixed racial 
groups, which compromised the quality of the final data. The dental survey of 
Ministry of Health have estimated prevalence of cleft lip as 1 in 700 while that of 
cleft palate to be 1 in 600 in Peninsular Malaysia in 1970 and this prevalence 
possibly reduced to 1 in 738 for cleft lip and 1 in 1230 for cleft palate in 1988 (Ghee, 
2001). Some authors found orofacial clefts in Malaysia to be 1 in 700 (Rahoma, 
2002). Malaysian data are currently based on surgical or orofacial experiences and 
epidemiological studies are not available. 
2.2 Classification of orofacial clefts  
Several classifications for oral clefts have been introduced over the years. 
The more detailed classifications describe the extent, symmetry and structures 
involved in the cleft (Coleman and Sykes, 2001, Smith et al., 1998). The severity of 
cleft lip can range from a slight notch in the upper lip to a complete cleft involving 
the nostrils (Merritt, 2005). Anatomically, orofacial clefts can simply be classified as 
cleft palate alone (CP) or cleft lip with or without cleft palate (CL/P). Cleft palate 
(CP) may involve soft and hard palates, or just the soft palate, but very rarely is the 
hard palate affected in isolation. The International Statistical Classification of 
diseases and health problems divides orofacial clefts according to the affected 
structures and location of defect, into eight cleft types / groups (Kernahan, 1971, 
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Wei, 1988). They include, bilateral total cleft lip, alveolar ridge and palate, unilateral 
total cleft lip, alveolar ridge and palate (left or right side), unilateral partially cleft lip 
and palate (left or right side), unilateral cleft of lip and alveolar ridge (left or right 
side), bilateral cleft of lip and alveolar ridge, bilateral cleft lip, unilateral cleft of lip 
(left or right side), and cleft of palate (soft or hard).  
2.2.1 Contemporary anatomical classification of orofacial clefts 
While anatomical alveolar ridge was the significant landmark in the division 
of oral clefts in earlier classifications, the incisive foramen, an embryological 
landmark, which marks the boundary between the primary palate and the secondary 
palate, was the point of demarcation in later classifications. The area anterior to the 
incisive foramen makes up the primary palate, which includes the lip and alveolus. 
Cleft lip includes those cases where the cleft is of the primary palate.  The secondary 
palate is posterior to the incisive foramen and includes the hard and soft palate. 
Orofacial clefts signify clefting of primary or secondary palate or both (Edwards, 
1980, Veau, 1931). Some of the anatomical types of orofacial clefts are shown in 
Appendix I. 
2.2.2 Genetic classification of orofacial clefts 
A widely used and accepted classification divides oral clefts into isolated 
malformations (nonsyndromic orofacial clefts) and associated with other 
malformations (syndromic) (Murray, 2002a). For our study purpose, we have taken 
cases of nonsyndromic orofacial clefts using the contemporary anatomical 
classification system describe above. Although they are usually isolated, 10% of all 
infants with orofacial clefts also have an associated syndrome. Thirty percent of 
patients with CL alone and 50% of cases of CP alone are syndromic (Wantia and 
Rettinger, 2002). Syndromic clefts are further subdivided as that due to chromosomal 
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disorders, known teratogen exposures, and uncategorized syndromes which has been 
described later. Nonsyndromic clefts occur in infants with no other physical or 
developmental anomalies except the CL and/or CP and with no known teratogen 
exposure (Bender, 2000). Orofacial clefts can be classified based on the genetic 
pattern of inheritance into the following types: (1) syndromic, which includes 
monogenic (single-gene disorders), chromosomal, and environmental etiologies (1 to 
8% of CL/P), (2)  familial where 2 or more family members including cousins have 
the same malformation which accounts for 12 to 25% of isolated CL/P; and (3) 
isolated or nonfamilial, which includes all kindred with only the proband (i.e. the 
first person in a pedigree found to have the defect) affected in first, second and third 
degree relatives (Bixler, 1981).  
2.3 Embryological origin of the orofacial clefts 
The facial structures begin to develop around the end of the fourth week of 
human development  (Moore, 1977, Sadler, 1990). Five facial prominences appear 
around the stomadeum or primitive mouth. These facial prominences are  the 
unpaired frontonasal prominence, paired maxillary prominences, and  paired 
mandibular prominences (Sadler, 1990).  These structures are diagrammatically 
shown in Figure 2.1. 
CLP consists of both CL and CP. However, Cleft lip (CL) and cleft palate 
(CP) have different embryologic origins. Cleft lip (CL) results from a failed union of 
the maxillary and medial nasal elevations on one or both sides. Cleft palate results 
from failure of the palatine processes to meet and fuse with each other. Cleft palate is 
more frequently associated with a syndrome, whereas CL is most often an isolated 
defect (Wong and Hagg, 2004). 
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Figure 2.1 Facial development at 45 intrauterine days [adapted from (Bender, 2000)] 
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2.3.1 Embryology of cleft lip  
During early embryonic craniofacial development, the 2 olfactory placodes 
invaginate to form nasal grooves that form the lateral boundaries of the frontonasal 
process. The placodes then begin to curl outward around the edges to give rise to the 
lateral and medial nasal processes, both of which grow and eventually fuse with the 
maxillary process to form much of the upper lip and primary palate. Fusion of these 
regions giving rise to the lip and primary palate (area in front of incisive foramen) 
takes place between 4th to 6th weeks of development. Any abnormality in the fusion 
process gives rise to cleft lip which may be unilateral or bilateral depending on 
anatomically whether the nasal process of one side or both sides fail to fuse with the 
maxillary process. Cleft lip can extend from gum margin up to incisive foramina 
(Kerrigan et al., 2000). 
2.3.2 Embryology of cleft palate  
Formation of the soft and hard palate (area behind the incisive foramen) 
occurs between 7th to 13th weeks. The periods from 6th to 9th weeks are the most 
crucial. It is a process which occurs after lip formation  (Bender, 2000). From the 
two sides the 2 maxillary processes give rise to ridges called the palatine shelves 
(Thornton et al., 1996). The palatine shelves grow horizontally and come to lie above 
the tongue. Later the shelves fuse forming the hard and soft palate which makes up 
the secondary palate. Next, the primary palate fuses with the secondary palate. The 
incisive foramen represents the midline landmark between the primary and 
secondary palates. The palate is thought to form strictly by midline fusion of the 
palatine shelves. Any defect in this process results in cleft palate. By 12 weeks, the 
fusion is complete and bone extends from the maxillae and palatine bones (Kerrigan 
et al., 2000).  
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2.4 Aetiology of orofacial clefts 
Orofacial clefts are a complex disorder of facial development. There are 
different factors involved in origin of this disorder. The syndromic orofacial clefts 
have clear genetic basis while the nonsyndromic disorder has many etiological 
factors as described in the following sections. Several genes and loci which have 
been implicated in the causation of this disorder are discussed. 
2.4.1 Aetiology of syndromic orofacial cleft 
A syndrome is a collection of findings occurring together in an individual (a 
syndrome means running together in Greek). Causes of syndromic orofacial clefts 
are often easily recognizable. They can be (a) monogenic disorders/ single gene 
disorders for example Van der Woude syndrome, Apert syndrome and Seckel 
syndrome. They follow the Mendelian mode of inheritance. Example of single gene 
syndromes are, Meckel syndrome, which is an autosomal recessive disorder and is 
associated with polydactyly, polycystic kidneys, encephalocoele, cardiac anomalies, 
and other abnormalities (Chung et al., 1986). Van der Woude syndrome, an 
autosomal dominant disorder is characterized by the presence of lip pits in lower lip 
(Cervenka et al., 1967). (b) Chromosomal disorders like Patau syndrome (trisomy 
13), trisomy 18, Turner syndrome, Down syndrome, Cri-du chat syndrome and Wolf-
Hirschhorn syndrome (Taylor et al., 1970, Smith, 1982, Gorlin, 1971). (c) Unknown 
cause. In syndromes like Pierre Robin syndrome associated with orofacial clefts, no 
single aetiology can be pin pointed.   
2.4.2 Aetiology of nonsyndromic orofacial clefts  
In isolated or nonsyndromic orofacial clefts, the aetiology is difficult to pin 
point. An interaction between genetic and environmental factors during a critical 
stage of development is thought to be responsible for these cases (Murray, 2002a, 
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Stanier and Moore, 2004). Genes play the more significant role in nonsyndromic 
orofacial clefts as there is a higher concordance rate for orofacial clefts in 
monozygotic twins (60%) than among dizygotic twins (10%) (Christensen et al., 
1999). This difference implies that genes have a major role to play in nonsyndromic 
orofacial clefts. However 40% discordance among monozygotic twins implies that 
environment influences are also important. Among the genes involved in the risk of 
orofacial clefts methylene tetrahydrofolate reductase (MTHFR) gene is important 
possibly because of its effect on environmental factor of folic acid deficiency. This 
gene and folate have been described in later sections. The environmental factors are 
postulated below. 
2.4.2a Environmental factors in aetiology of nonsyndromic orofacial clefts  
The factors for the aetiology of nonsyndromic orofacial clefts are (a) 
Nutritional deficiency: An environmental component to clefting was recognized 
when Warkany (1943), associated nutritional deficiencies with cleft palate (Warkany 
et al., 1943). Folate, B6 and B12 deficiencies have been studied with variable 
findings (Lettieri, 1993). The role of folate supplementation in pregnancy in 
prevention of orofacial clefts has been elaborated in Section 2.7.3. (b) Infections: 
Infections during pregnancy can produce birth defects. These are considered 
environmentally induced defects. During pregnancy it is important to be cautious 
about which medications are taken and cautious about being exposed to viral 
infections, such as the cytomegalovirus or the rubella virus (Thornton et al., 1996). 
(c) Drugs: There are many factors which influence the development of birth defects 
when a pregnant mother is exposed to a teratogen. Some of the factors which 
determine the impact of a teratogen include the genotype of the mother and the child 
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and the timing and the dose of the drugs (Isreal, 1987). A drug, for example, cannot 
affect the development of a cleft lip or palate if it is taken by the mother after the 
closure of the lip and the palate in utero. Recognized teratogens that cause clefts 
include rare exposures, such as phenytoin, valproic acid and thalidomide; and also 
common environmental exposures, such as maternal alcohol or herbicides such as 
dioxin (Garcia et al., 1999). Apart from anti-epileptic medication, other drugs have 
been implicated in cleft palate. Corticosteroid exposure in the first trimester of 
pregnancy increases the risk of orofacial clefts in offspring (Rodriguez-Pinilla and 
Martinez-Frias, 1998, Carmichael and Shaw, 1999). Prednisolone increases the risk 
of orofacial clefts by 3-4 folds (Park-Wyllie et al., 2000). (d) Cigarette smoking: 
Maternal smoking has been associated with increased risk for oral clefts especially 
during first trimester of pregnancy as shown by (Wyszynski and Beaty, 1996). Of all 
other congenital malformations orofacial clefts is possibly most definitely associated 
with smoking and there is enough evidence showing the positive association (Chung 
et al., 2000, Lieff et al., 1999). The mechanism by which cigarette smoke 
detrimentally affects pregnancy outcome is not well understood but some authors 
suggest a gene environment interaction by polymorphisms involving 
biotransformation genes resulted in congenital malformation due to cigarette smoke 
(van Rooij et al., 2001). 
2.4.2b Genes and loci in the etiology of nonsyndromic orofacial clefts  
Fogh-Andersen first defined genetic factors involved in orofacial clefting, 
which were later confirmed by other authors (Marazita et al., 1986b, Fogh-Andersen, 
1942). To date no single gene has been identified as a universal explanation for all 
cases of isolated orofacial clefts (Kerrigan et al., 2000). Possibly different genes are 
